Vivace Therapeutics announces dosing of first cohort of patients with its first-in-class TEAD inhibitor
Share this article Share this article SAN MATEO, Calif., May 4, 2021 /PRNewswire/ -- Vivace Therapeutics, Inc., a small molecule discovery and development company developing first-in-class therapies targeting the Hippo pathway, announced today the completion of enrollment of the first cohort of patients being treated with VT3989 in its Phase 1 clinical study. The Company anticipates enrolling the next higher dose cohort in the second part of May. The VT3989 Phase 1 study is now open at centers in both the US and Australia (https://clinicaltrials.gov/ct2/show/NCT04665206) to evaluate the s...